Research Paper Volume 16, Issue 16 pp 12029—12049

Figure 5. UBR1 expression is associated with GC progression. (A) UBR1 expression levels in patients with stage T3 and T4 gastric cancer (GC) compared to those with stage T2, based on the GEO dataset GSE84437. (B) UBR1 expression levels in patients with stage N1 and N2 GC compared to those with stage N0, from the GEO dataset GSE84437. (C) UBR1 expression levels in GC patients aged 65 years and older compared to younger patients, using data from the GEO dataset GSE84437. (D) UBR1 expression levels in male GC patients compared to female patients, based on the GEO dataset GSE84437. (E) UBR1 expression levels in patients with T4 stage GC, according to TCGA database data. (F) UBR1 expression levels in stage III GC patients compared to stage II patients, from the TCGA database. (G) UBR1 expression levels in tumors with sarcoid residual (R2) compared to those with complete tumor resection (R0), based on TCGA data. (H) UBR1 expression levels in patients who did not receive anti-reflux treatment, according to TCGA data. (I) Fan charts illustrating variations in UBR1 expression across different clinical prognostic stages. (J) Nomograms showing the relationship between UBR1 expression and various clinical prognostic factors in GC.